A 28-year-old woman from Delhi presents to the gynecology clinic with a 3-year history of irregular menstrual cycles and progressive weight gain of 12 kg. She reports hirsutism on the face and abdomen, and acne on the cheeks. Menarche was at age 13 with initially regular cycles. On examination: BMI 28 kg/m², blood pressure 128/82 mmHg, Ferriman–Gallwey score 12. Pelvic ultrasound shows bilateral ovarian cysts (8–10 mm) with increased stroma. Fasting blood glucose 92 mg/dL, insulin 18 mIU/mL (normal <12). FSH 6 mIU/mL, LH 16 mIU/mL, testosterone 0.8 ng/mL (normal <0.7). What is the most appropriate first-line pharmacological intervention for her menstrual irregularity and metabolic dysfunction?

Explanation

## Clinical Diagnosis: PCOS with Insulin Resistance This patient meets Rotterdam criteria for PCOS: - Oligomenorrhea (irregular cycles × 3 years) - Clinical hyperandrogenism (hirsutism, acne) - Polycystic ovaries on ultrasound - Elevated LH:FSH ratio (16:6 ≈ 2.7:1) - Elevated fasting insulin with normal glucose (HOMA-IR ~4.1, indicating insulin resistance) ## Why Metformin is First-Line Here **Key Point:** Metformin is the first-line pharmacological agent for PCOS with insulin resistance because it: 1. Reduces hyperinsulinemia and improves insulin sensitivity 2. Restores ovulatory cycles in 30–40% of women 3. Promotes modest weight loss (1–3 kg) 4. Reduces progression to type 2 diabetes (31% risk reduction) 5. Is safe, well-tolerated, and has metabolic benefits beyond contraception **High-Yield:** The elevated fasting insulin (18 mIU/mL) is the key finding that mandates metformin. This patient has insulin resistance, which is the pathophysiologic driver of PCOS in 70–80% of cases. ## Role of Other Agents | Agent | Indication | Role in This Case | |-------|-----------|-------------------| | **Combined OCP** | Hyperandrogenism, menstrual regulation | Second-line if metformin alone insufficient; used *after* metabolic optimization | | **Spironolactone** | Severe hirsutism/acne | Adjunctive only; not first-line for menstrual disorder | | **GnRH agonist** | Severe hyperandrogenism, endometriosis | Contraindicated in PCOS; suppresses FSH/LH further | **Clinical Pearl:** In lean PCOS (BMI <25), metformin is still offered but weight loss is the primary intervention. In obese PCOS (BMI ≥25, as here), metformin + lifestyle modification is standard of care. ## Treatment Algorithm ```mermaid flowchart TD A[PCOS diagnosis confirmed]:::outcome --> B{Insulin resistance present?}:::decision B -->|Yes: elevated fasting insulin| C[Metformin 500 mg BD-TDS]:::action B -->|No: normal insulin| D[Combined OCP]:::action C --> E[Reassess at 3 months]:::decision E -->|Cycles regular, hirsutism improved| F[Continue metformin]:::outcome E -->|Inadequate response| G[Add combined OCP]:::action D --> H[Menstrual regulation + androgen suppression]:::outcome ``` **Mnemonic:** **METFORMIN in PCOS** = **M**etabolic **E**valuation **T**hen **F**irst-line **O**ral **R**egulator **M**inimizes **I**nsulin **N**eeds.